—•Today is •—

Employment Listings SAS® Users Joseph Associates icrunchdata.com SAS Job Web SAS-Jobs MRA Six Sigma Training & Certification SixSigmaOnline.org isixsigma.com Statistical Resources Statistical Graphics Bayesian SAS-L Textbook R Project StatLib Customer Relationship Management Jim Novo CRM-Forum Search CRM CRM Community ITtoolbox CRM destinationCRM internet.com CRM List of Current Projects ACEI/ARBs COPD Proteinurea Quality Control REP STEM

Proteinurea Detection and Treatment Study Posted: 12/8/2003 Study Population: The study population includes members age 18 and older who were previously diagnosed with diabetes (ICD-CM Code: 250.xx) during the time frame period of August 1, 2002 to February 28, 2003. Objectives: It evaluates the use of anti-hypertensive drugs among members diagnosed with diabetes only and members with diabetes coexisting essential hypertension (ICD-9 CM Code: 401.xx) showing proteinurea tests. Because proteinurea is the principle surrogate for diabetic renal disease, its detection and treatment can be significant determinants for slowing the progression of nephropathy (which common cause of end-stage-renal disease ESRD) and decreasing morbidity and mortality. This study also measures the effectiveness of patient-physician outreach program encouraging proteinurea screening and appropriate use of anti-hypertensive drugs. Initial/Utilization Reports: identifies members diagnosed with diabetes and members diagnosed with diabetes coexisting essential hypertension either a primary or secondary diagnosis. View Result identifies members who were using anti-hypertensive drugs and members who were not using anti-hypertensive drugs. View Result members using anti-hypertensive drugs with two or more consecutive scripts and should have at least 100 days apart (calculation was based on the date filled). View Result Frequency counts of all anti-hypertensive drugs listing by class. View Result identifies members who had proteinurea screen tests and selects members' latest test results to stratify into categories: positive albuminurea (29 >), negative albuminurea (< 29), microalbuminurea (30 - 299), and clinical albuminurea (300 >). View Result Lab A View Result Lab B combined two different lab data to determine which which lab had the first test and find if there's any lab test done on the same day. View Result total number of members without proteinurea screen tests View Result Study Groups: Data analyses and interventions were based on the two study groups and each group was subdivided into six study groups and defined as follows: Group A - not using anti-hypertensive drugs View Result Group B - anti-hypertensive drugs users View Result Group B - anti-hypertensive drugs users with two or more consecutive scripts View Result Anti-hyperensive drugs by class identifying only ACE Inhibitors (ACEI) and Angiotensin II Receptor Blockers (ARBs) View Result

[Video Poker] [Arrange] [Crystal Ball] [Tic Tac Toe] [Reflex] [Memory] [Battleship] [Blackjack] [Trivia] [Math Game] [Pokemon] [Box-In]

Copyright © 2002-2004 www.nycinformatics®.com All Rights Reserved SAS product or service names are registered trademarks of SAS Institute, Inc. in the USA and other countries. ® indicates USA registration.